Elevated levels of NR2F1-AS1 have been documented in cancers such as breast cancer [25–27], gastric cancer [28–31], bladder cancer [32–34], thyroid cancer [35–37], hepatocellular carcinoma [38–41], non-small cell lung cancer [44], osteosarcoma [42, 43], esophageal squamous cell carcinoma [45, 46], pancreatic ductal adenocarcinoma [53], neuroblastoma [47], melanoma [48], and endometrial cancer [49] (Fig. 1). Here, NR2F1 is linked to melanoma.